Aravive to Participate in H.C. Wainwright Global Investment Conference

Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company, will present at the H.C.

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company, will present at the H.C. Wainwright Annual Global Investment Conference from May 23-26, 2022. CEO Gail McIntyre will speak on May 25, 2022, from 10:00 am to 10:30 am ET at the Fontainebleau Miami Beach Hotel. Aravive focuses on developing targeted therapeutics for metastatic disease, with its lead candidate, batiraxcept, granted Fast Track and Orphan Drug Designations in ovarian cancer. The company is conducting multiple trials for batiraxcept in different cancer types. For more details, visit www.aravive.com.

Argus Session date unavailable

-1.79% session move Open Argus

Details

News Market Reaction – ARAV

The recorded move for ARAV in the trading session of this news was -1.79%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present at the H.C. Wainwright Annual Global Investment Conference being held at the Fontainebleau Miami Beach Hotel May 23-26, 2022.

What: H.C. Wainwright Annual Global Investment Conference
Where: Fontainebleau Miami Beach Hotel
When: May 25, 2022, 10:00 am ET – 10:30 am ET
Live and archived webcast: https://ir.aravive.com/events-and-presentations

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

Contact:
Marek Ciszewski, J.D.
Vice President, Investor Relations
Marek@Aravive.com
(562) 373-5787

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aravive present at the H.C. Wainwright Annual Global Investment Conference?

Aravive will present on May 25, 2022, from 10:00 am to 10:30 am ET.

Where is the H.C. Wainwright Annual Global Investment Conference being held?

The conference is held at the Fontainebleau Miami Beach Hotel.

What is batiraxcept and its significance for Aravive?

Batiraxcept is Aravive's lead product candidate, designed to treat metastatic disease and has received Fast Track and Orphan Drug Designations.

What clinical trials is Aravive currently conducting?

Aravive is conducting an active registrational Phase 3 trial in platinum-resistant ovarian cancer and additional trials for renal cell carcinoma and pancreatic adenocarcinoma.

How can I access the live webcast of Aravive's presentation?

The live and archived webcast can be accessed at https://ir.aravive.com/events-and-presentations.